MP Advisors - Independent Research Provider - Fundamental BioPharmaceuticals

MP Advisors is an independent investment research firm founded in 1996 with an exclusive speciality in the Pharmaceuticals / Biotechnology sector. Formerly, it was the international affiliate of Mehta Partners LLC. MP Advisors has a highly qualified team of analysts, researchers and financial professionals who exercise the use of proprietary data bases, tools, relevant company and regulatory websites to assemble, assimilate, analyze and interpret the latest and most trustworthy information essential, to explore investment opportunities through fundamental assessment. MP Advisors has insightful information on more than 200 pharma and Biotech companies across the globe as well as publishes timely reports on Para IV litigations, Key opinion leaders (Physician’s view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity etc.) and Japan generic opportunities.

We cast a wide net to unearth the best investment opportunities. Our coverage spans the globe and includes all market caps, offering built-in diversification for investors seeking to compose a sector portfolio with low volatility. We cover  over 70+ companies and monitor   ~150 promising names. Our conclusions include in-depth analysis of long-term (>1year) investment opportunities along with constant reappraisal of selected short-term (3-6 months) ideas.

BioPharma Outlook

We've helped investors navigate the dynamic BioPharma industry for decades. Our flagship publication, BioPharmaceutical Outlook™ maps the highs and lows of the year, assessing the critical success factors that can shape the industry's future.

Based on extensive research and comprehensive data analysis, this volume is a ready reference for monitoring new developments and their investment and strategic implications. From the macro analysis of over 200 companies arise ~40+ actionable capsules categorized into Global Pharma, Japanese Pharma, Mature Biotech, Rising Stars (unprofitable biotech) and Indian Pharma.

Para IV Plus

Information on brand name, generic name, innovators and probable FTF Holder(s). Select your preferred search option for detailed reports. Para IV Plus is a knowledge bank of ongoing pharma patent litigations covered in the most comprehensive manner. Currently it covers ~400 product patent litigations – i.e. patent litigations involving global as well as non global innovator companies.

What does Para IV Plus contain?

1. A comprehensive legal understanding of each product as regards its litigation and also measures taken outside of courts (like settlements, Citizen Petitions etc.)
2. Identifying cases that are not litigated and claims of generics accepted by innovators – something that never comes to the public domain until the launch of the generic.
3. An attempt to anticipate (and not speculate) to find ‘what could be next’, including possible settlements, possible at risk launches, possible launches as per undisclosed settlement dates, based on available facts.
4. In other words, Para IV Plus is not merely a database but is a tool with in-depth insights for every product (and not just every litigation) such that an expert in the field can easily gauge opportunities for various parties.
5. The Advanced Search feature helps in company analysis & product analysis in different permutations & combinations. Eg. list of products belonging to Pfizer with sales of more than $500m where Teva is the FTF, along with date of generic launch by Teva as well as other generics thereafter.

Strategic Advisory Services

Strategic Collaborations are a marathon and require sincere dedication: We smoothen the strategic path with a deep knowledge of the industry, the finesse to judge the psyche of various stakeholders-not to mention the nuances of the whole process. Advanced research, learning as much about our clients and consulting with them lends us an expertise to advice the feasibility of a deal or how to make a business more profitable. We work hands on with our clients and welcome a chance to be a part of your team. 

Institutional Advisory Services

Innovation, socio-economic and political changes are transforming the BioPharma industry and call for an in-depth and globally integrated understanding of new opportunities. Enter MP Advisors.